

### EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with the attorney Ruth Tyler-Cross on 11/3/09 and 1/22/10.

The application has been amended as follows:

In the claims

Claim 12 was amended as follows:

--- of ---- was inserted after "that" on second line.

"and, when" on 6<sup>th</sup> line was deleted and replaced with --- determining that ---.

"when" on 9<sup>th</sup> line was deleted and replaced with --- determining that ---.

"then concluding that" on lines 11<sup>th</sup> and 12<sup>th</sup> was deleted and replaced with --- wherein displacement of the binding of epigallocatechin gallate by the catechin or antibody indicates that ---.

"the compound having a galloyl group" on line 13<sup>th</sup> was deleted and replaced with --- epigallocatechin gallate ---.

"the compound having a galloyl group" on lines 13<sup>th</sup> and 14<sup>th</sup> was deleted and replaced with --- epigallocatechin gallate ---.

Claim 13 was amended as follows:

“as a result of the competition, and when” on line 7<sup>th</sup> was deleted and replaced with --- determining that --.

“then concluding” on lines 9<sup>th</sup> and 11<sup>th</sup> was deleted and replaced with --- wherein displacement of the binding of epigallocatechin gallate by the catechin or antibody indicates ---.

**2.** The following is an examiner’s statement of reasons for allowance:

The art does not teach or suggest a method for screening a catechin or an antibody that has the same growth-inhibiting effect on cancer cells as epigallocatechin gallate, comprising determining displacement of the binding of epigallocatechin gallate to the full length 67 kDa laminin receptor expressed on the cell surface cancer cells by the screened catechin or antibody.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.”

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINH-TAM DAVIS whose telephone number is 571-272-0830. The examiner can normally be reached on 9:00 AM-5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, LARRY HELMS can be reached on 571-272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1642

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MINH-TAM DAVIS

January 23, 2010

/Larry R. Helms/

Supervisory Patent Examiner, Art Unit 1643